Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor–Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis
Ian Hennessee, Kaitlin Benedict, Nathan C. Bahr, Shari R. Lipner, Jeremy A.W. Gold
Abstract
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.
Topics & Concepts
MedicineRheumatoid arthritisInflammatory bowel diseaseIncidence (geometry)ImmunologyInternal medicineArthritisDiseaseTumor necrosis factor alphaHistoplasmosisGastroenterologyPhysicsOpticsAntifungal resistance and susceptibilityFungal Infections and StudiesInflammatory Bowel Disease